Ann: First-in-human Study Progress Update, page-169

Hi Kickerz, while we don't know for sure the exact number of patients recruited for the trial so far, we
do know (as you mentioned) that "the first five patients completed the study" with no safety issues
reported. Also of interest was that the imaging agent used is capable of reaching the lymph nodes.

So, the trial continues with purposeful and sincere intent and I believe that any prospective patient now
contemplating their participation in this study will now do so far more enthusiastically with the knowledge
that safety concerns with the study have been mitigated or diminished.

The positive spinoff from this is that the study should now find that patient recruitment is accelerated with
any initial safety concerns that patients may have had have now been seriously allayed.
To me, (primarily viewed through my lenses) this translates to a much earlier completion date for the study
and therefore, we should see scale-up activities that support more development and clinical studies much
sooner than anticipate.

That's my perspective and interpretation.